Navigation Links
ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
Date:1/5/2011

IRVINE, Calif., Jan. 5, 2011 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today, during its previously announced guidance call, that it expects to achieve its 2010 net revenues guidance of $147 million to $167 million with anticipated, unaudited net revenues in the mid-$150 million range.  The company also said it expects to exceed $1 million in unaudited net income in 2010, before any warrant expense.

President and Chief Executive Officer Vicente Anido, Jr., Ph.D., said, "ISTA has established itself as a successful pharmaceutical developer, an aggressive competitor and a fast-growing, profitable specialty pharmaceutical company. We've managed effectively through the company's start-up phase, obtained FDA approval to market five drugs in just six years, and established a formidable sales force calling on ophthalmologists, optometrists and allergists.  In 2010, we achieved revenue growth of about 40% as compared to 2009, while delivering our first year of profitability."

2011 Financial Outlook in Detail

On today's guidance call, Chief Financial Officer and Vice President of Corporate Development Lauren Silvernail reiterated the company's 2011 revenues guidance provided on the third quarter 2010 earnings call and gave additional detail on revenue, expenses, income and cash.  ISTA expects:  

  • 2011 net revenues will be approximately $175 million to $190 million.
  • 2011 gross margins will be in the 75% to 77% range.
  • 2011 R&D expenses will be 18% to 22% of net revenues.
  • 2011 SG&A expenses will be 44% to 48% of net revenues.
  • 2011 operating income will be $13 million to $16 million.
  • 2011 net income will be $5 million to $8 million, or fully diluted earnings per share of $0.11 to $0.18, assuming 44 million fully diluted shares and
    '/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... N.Y. , July 2, 2015  Before you head ... ahead so you can stay safe and healthy. Take steps ... #summersafety. Infographic http://nyackhospital.org/summersafety Protect Your Skin ... from the sun can increase your risk of skin cancer. ... shade as much as possible, especially during midday hours. Wear ...
(Date:7/2/2015)... According to a new market research report " ... Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, Ischemia, ... the global Neuromodulation Market is estimated at $3.65 Billion in ... at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
Breaking Medicine Technology:First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... , ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, announced today ... demonstrating the effectiveness of Valortim® in an inhalation anthrax ... The data are being presented during an oral session ...
... , BILLERICA, Mass., Dec. 4 ... (Nasdaq: VOLC ), today announced the initial development and ... OCT imaging. Axsun believes this proprietary optical engine design ... of laser-based designs for swept source OCT light sources. ...
Cached Medicine Technology:PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
(Date:7/2/2015)... LENEXA, Kan. (PRWEB) , ... July 02, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... One of the top executive search firms in the healthcare industry, B. E. ...
(Date:7/2/2015)... ... ... Throughout the month of April, Casey’s General Stores invited customers to give ... 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a check to ... nonprofit dedicated to restoring a sense of self, restoring the family unit, and restoring ...
(Date:7/2/2015)... ... 2015 , ... AvePoint Public Sector, Inc., a wholly owned subsidiary ... today announced it was named the recipient of the 2015 GTRA ConVurge Tech Award ... by the Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge ...
(Date:7/2/2015)... ... July 02, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it has made two ... is the new General Manager at Catalent’s Schorndorf facility, which provides large scale, ...
Breaking Medicine News(10 mins):Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... people with skin care information from their most ... insights are provided by skin care experts with ... The content is written by experts in skin ... advice. Key portions of the service include information ...
... Slimband employees successfully competed in the 19th Annual Canada Life CN Tower Climb ... ... 22, 2009-- A team of Slimband employees successfully competed in the ... April 16th. The CN Tower Climb is a demanding competition in which ...
... continues to follow her treacherous sister Notre Dame ... 22 Georgetown University continues to follow ... with award, pro-lifers to protest.On Wednesday, April 22, starting ... will protest at Georgetown Law Center, McDonough Hall, 600 ...
... 21 When Gundersen Lutheran Health System set out to ... 2 percent decrease that,s common at healthcare facilities. Instead, they,re ... than two years. That,s 9,600 metric tons of carbon dioxide ... of removing 1,631 cars from the road. The La Crosse, ...
... OKLAHOMA CITY, April 21 Costs to families and ... to the neighborhood gas station. That is why it ... affordable and accessible to all Oklahomans. Holding down the ... task, but controlling costs is a challenge we can ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
Cached Medicine News:Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2Health News:Slimband™ Team Competes in CN Tower Climb and Helps Fight Against Global Warming 2Health News:Anti Abortion Protesters will be at VP Biden Award at Georgetown Law School 2Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Refuting Misconceptions About Health Insurance Mandates 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
300 L, Bulk Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
Medicine Products: